Galderma Group AG (GALDY)
| Market Cap | 43.68B |
| Revenue (ttm) | 4.69B |
| Net Income (ttm) | 378.00M |
| Shares Out | n/a |
| EPS (ttm) | 1.59 |
| PE Ratio | 115.56 |
| Forward PE | 45.05 |
| Dividend | 0.02 (0.06%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 23,711 |
| Average Volume | 35,864 |
| Open | 36.57 |
| Previous Close | 36.43 |
| Day's Range | 36.57 - 37.31 |
| 52-Week Range | 17.27 - 37.45 |
| Beta | n/a |
| RSI | 60.65 |
| Earnings Date | Oct 31, 2025 |
About Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes ACTINICA, Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, Mirvaso, NEMLUVIO, Relfydess, Benzac, Loceryl, and TRI-LUMA in therapeutic dermatology. ... [Read more]
Financial Performance
Financial StatementsNews
EQT completes sale of shares in Galderma Group AG
STOCKHOLM, Oct. 30, 2025 /PRNewswire/ -- Further to previous announcements, an affiliate of the funds known as EQT VIII ("EQT") is pleased to announce the completion of the placement of 20 million sha...
Galderma Group AG (GALDY) Q3 2025 Sales Call Transcript
Galderma Group AG (OTCPK:GALDY) Q3 2025 Sales Call October 23, 2025 9:30 AM EDT Company Participants Emil Ivanov - Head of Strategy, Investor Relations & ESG Flemming Ornskov - CEO & Director Thomas J...
Galderma Delivers Record Net Sales of 3.737 Billion USD in the First Nine Months of 2025 and 15.0% Year-on-Year Growth at Constant Currency, Raises Full-Year Guidance
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first nine months of 2025, delivering record n...
AMWC Dubai: Galderma Demonstrates Injectable Aesthetics Leadership Through Updates on Its Scientific Innovations and Community Education
ZUG, Switzerland--(BUSINESS WIRE)--Galderma will present six posters with the latest updates from its science-backed aesthetic portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) in...
Galderma's Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin
ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced new data from a first-of-its-kind real-world clinical study conducted in China assessing the biological impact of different lifestyles and t...
EADV 2025: Galderma Reinforces Leadership in Dermatology With Latest Advances in Sensitive Skin and Itch
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the dermatology category leader, today announced it will unveil updates from its portfolio at the 34th European Academy of Dermatology and Vene...
Galderma Launches Alastin® in China, Supporting the Skin's Natural Regenerative Abilities in a Rapidly Expanding Market
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced the launch of four core Alastin® products in China, marking the premium medical skincare brand's debut in one of the world's fas...
Chocolate, skincare and timepieces: What 39% tariffs on Swiss goods mean for U.S. consumers
Switzerland is facing potential U.S. tariffs of 39% if a deal is not struck by Thursday. Consumers will mostly be familiar with the Alpine country's high-end products, from Rolex watches to premium be...
Galderma Announces Departure of Its Chief Financial Officer
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that Thomas Dittrich, Chief Financial Officer, will be leaving the company t...
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of ...
Galderma establishes new U.S. headquarters in Miami and strengthens regional leadership
Strategic move aims to accelerate innovation and growth in the U.S., Galderma's largest region MIAMI , June 17, 2025 /PRNewswire/ -- Galderma (SIX: GALD), the pure-play dermatology category leader, to...